This document summarizes a study that analyzed the risk and benefits of metformin use in diabetic patients undergoing secondary cardiovascular prevention. The study found that among 28,700 diabetic patients, those taking metformin had a 25% lower risk of all-cause mortality over 2 years compared to those not taking metformin, even after adjusting for differences in patient characteristics. Metformin use was associated with reduced mortality risk across most patient subgroups, with the largest benefits seen in those with a history of heart failure or those using insulin. The results suggest metformin may provide unexpected survival benefits in high-risk diabetic patients.